MSK Awards & Appointments July 2023

Share
MSK Awards & Appointments January 2023

Memorial Sloan Kettering Cancer Center (MSK) today announced the following awards and appointments: 

MSK Named Finalist for the 2023 U.S. Legal Department of the Year

MSK’s Legal team has been recognized as of one of five finalists for the 2023 U.S. Legal Department of the Year award by the American Lawyer/Corporate Counsel, the leading legal industry publication. Our legal team competed for this recognition against all other U.S. in-house legal departments of all sizes. The winner will be announced in November at The American Lawyer Industry 2023 Awards dinner. This award recognizes U.S. legal departments that have surmounted extreme challenges, exhibited innovative thinking, and achieved measurable successes.

Omar Abdel-Wahab Received the William Dameshek Prize

Omar Abdel-Wahab, MD, leukemia specialist, Chair of the Molecular Pharmacology at the Sloan Kettering Institute, and Edward P. Evans Endowed Chair for MDS, received the William Dameshek Prize from the American Society of Hematology (ASH). The William Dameshek Prize is awarded each year to an individual who has made outstanding contributions in hematology. Dr. Abdel-Wahab was recognized for his trailblazing research characterizing the genetic mutations that drive blood cancers.

Santosha Vardhana Received the Damon Runyon Cancer Research Foundation Clinical Investigator Award

Santosha Vardhana, MD, PhD, Assistant Attending Physician, along with mentor Charles Sawyers, MD, Chair of the Human Oncology and Pathogenesis Program and Marie-Josée and Henry R. Kravis Chair in Human Oncology and Pathogenesis, received the Damon Runyon Clinical Investigator Award. This prestigious award is granted to outstanding, early-career physician-scientists conducting patient-oriented cancer research at major research centers under the mentorship of the nation’s leading scientist and clinicians. The Clinical Investigator Award program was designed to increase the number of physicians capable of moving seamlessly between the laboratory and the patient’s bedside in search of breakthrough treatments.

Luis Diaz Named One of the Most Creative People in Business 2023 by Fast Company

Luis Diaz Jr., MD, medical oncologist, Head Division of Solid Tumor, and Grayer Family Chair, was named one of the Most Creative People in Business by Fast Company for his groundbreaking work in unleashing the immune system on hard-to-treat cancers and leading a clinical trial in patients with advanced MMR-deficient rectal cancer that had a miraculous 100 percent success rate.

Charles B. Simone Received the American Society for Radiation Oncology Fellow Designation

Charles B. Simone, MD, radiation oncologist and Chief Medical Officer of the New York Proton Center, received the American Society for Radiation Oncology (ASTRO) Fellow designation. The ASTRO Fellows program recognizes individuals who have made substantial contributions to the Society and the field of radiation oncology through research, education, and patient care.

MSK Named One of America’s Best Cancer Hospitals by Newsweek

Newsweek ranked MSK #2 in their 2023 America’s Best Cancer Hospitals list. This ranking awarded leading hospitals providing cancer care in the United States. Results were compiled, and awards were presented based on three data sources—a nationwide online survey, hospital quality metrics, and patient experience.

Neeta Pandit-Tasker Received the Society of Nuclear Medicine and Molecular Imaging Henry N. Wagner, Jr., Abstract of the Year

Neeta Pandit-Taskar, MD, nuclear medicine physician and early drug development specialist, received the Henry N. Wagner, Jr., Abstract of the Year from the Society of Nuclear Medicine and Molecular Imaging (SNMMI) for her abstract, “Novel Molecularly Targeted I-131 Apamistamab Enables Marrow Transplantation with Long-term Survival in Relapsed/Refractory Acute Myeloid Leukemia. Each year, SNMMI chooses an abstract that best exemplifies the most promising advances in the field of nuclear medicine and molecular imaging.

Eileen O’Reilly Elected to the Pancreatic Cancer Action Network’s Scientific and Medical Advisory Board

Eileen O’Reilly, MD, gastrointestinal oncologist, Winthrop Rockefeller Endowed Chair of Medical Oncology, Co-Director of Medical Initiatives at the David M. Rubenstein Center for Pancreatic Cancer Research, and section head for hepatopancreaticobilary and neuroendocrine cancer, was elected to the Pancreatic Cancer Action Network’s (PanCAN) Scientific and Medical Advisory Board (SMAB). PanCAN’s SMAB includes distinguished scientists, clinicians, and healthcare professionals who specialize in pancreatic cancer from institutions across the United States. The SMAB provides scientific and clinical expertise to guide PanCAN in planning and implementing its research initiatives, as well as its in-depth information, resources and services for patients, caregivers, and healthcare professionals.

Oscar Lahoud Featured in Top Doctors of Long Island by Newsday

Oscar Lahoud, MD, bone marrow transplant specialist and cellular therapist, was featured in the 2023 issue of Top Doctors of Long Island by Newsday. In an article titled “The Latest Treatments on Long Island,” Dr. Lahoud discusses CAR T cell therapy treatment offered to patients with blood cancer at MSK Commack and MSK Nassau.

Eric Rosenbaum Named a Crain’s New York 2023 Notable Leaders in Advertising, Marketing and PR List

Eric Rosenbaum, Vice President of Brand, Advertising, and Creative Services, was named a Notable Leaders in Advertising on Crain’s New York Business 2023 list. The list recognized 75 individuals who can spot trends, gauge demographics, harness language, craft narratives, shape visuals, and conduct impactful campaigns.

Randy Yeh Awarded the Society of Nuclear Medicine and Molecular Imaging Mars Shot Research Fund

Randy Yeh, MD, radiologist and nuclear medicine physician, was awarded the Society of Nuclear Medicine and Molecular Imaging Mars Shot Research Fund. The grant recognizes individuals who have made transformative impact in the field and elevated the value of nuclear medicine and molecular imaging. Dr. Yeh was selected based on his proposal, “HER2 PET Imaging as Assess HER2 Heterogeneity and Predict Response to Trastuzumab-Deruxtecan in HER2-low Breast Cancer.”